Ganguly P K, Mukherjee K, Sahai A
Department of Anatomy, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Mol Cell Biochem. 1995 Mar 9;144(1):81-4. doi: 10.1007/BF00926744.
The present study examined the effect of fenoldopam, a known dopamine-1 receptor (DA1) agonist in order to understand its involvement in the cardiac hypertrophic process. Male Sprague-Dawley rats underwent abdominal aortic constriction (AB) with placement of a suprarenal ligature while sham operated animals served as controls. The AB groups showed an increase in their heart wt, left ventricular (LV) wt, heart wt/body wt and LV wt/body ratio. Furthermore, the length of these hearts, as measured from the auriculoventricular border to the apex, LV wall and interventricular (IV) septal thickness were increased from control levels. Treatment with SCH 23390, a DA1 antagonist, on the other hand, was able to partially regress the cardiac hypertrophic changes. All these parameters were also increased in control animals treated with fenoldopam (F). Such changes were more striking in the F+AB group which showed a significant acceleration of the cardiac hypertrophic process on superimposing the two treatments. Plasma dopamine and renin activity were increased in all the groups as compared to control. These results indicate that dopamine receptors are implicated in the development of cardiac hypertrophy.
本研究检测了已知的多巴胺 -1 受体（DA1）激动剂非诺多泮的作用，以了解其在心脏肥厚过程中的作用机制。雄性斯普拉格 - 道利大鼠接受腹主动脉缩窄（AB）并放置肾上腺结扎线，而假手术动物作为对照。AB 组的心脏重量、左心室（LV）重量、心脏重量/体重和 LV 重量/体重比均增加。此外，从房室交界处到心尖测量的这些心脏的长度、LV 壁厚度和室间隔（IV）厚度均高于对照水平。另一方面，用 DA1 拮抗剂 SCH 23390 治疗能够部分逆转心脏肥厚性变化。在用非诺多泮（F）治疗的对照动物中，所有这些参数也都增加。在 F + AB 组中，叠加两种治疗后心脏肥厚过程显著加速，这种变化更为明显。与对照组相比，所有组的血浆多巴胺和肾素活性均增加。这些结果表明多巴胺受体与心脏肥大的发生有关。
